IOL Chemicals & Pharmaceuticals Q2 FY27 Net Profit More Than Doubles To ₹65 Crore, Revenue Up 40.1%

IOL Chemicals & Pharmaceuticals Ltd. announced a remarkable surge in profits and revenue for the second quarter of fiscal year 2027, with net profit more than doubling to ₹65 crore. Revenue from operations also saw a substantial growth of 40.1 per cent, reaching ₹795 crore during the same period. The company's earnings before interest, tax, depreciation, and amortisation (EBITDA) increased by 79.6 per cent, reaching ₹114.9 crore.

The company's profitability improved significantly, with the EBITDA margin expanding by 321 basis points to 14.4 per cent, and the PAT margin increasing by 290 basis points to 8.1 per cent. In the first half of fiscal year 2027, revenue from operations grew by 38.6 per cent to ₹1,551.3 crore, and PAT more than doubled, reaching ₹129.5 crore.

The pharmaceutical segment of the business experienced robust growth, with revenue from the non-Ibuprofen portfolio increasing by approximately 70 per cent year-on-year, accounting for 45 per cent of pharmaceutical revenue during the quarter. The Chemicals business also showed improvement, with its EBIT contribution growing to approximately 7 per cent from 1 per cent in the corresponding quarter last year.

IOL Chemicals unveiled a ₹495 crore expansion plan, aiming to increase Ibuprofen capacity by 50 per cent. The company's management attributed its strong performance to healthy demand for key products and improved operational efficiencies. They anticipate further growth through forward integration into contract development and manufacturing organizations (CDMO) and formulation manufacturing, as well as portfolio diversification and expanding their presence in higher-value manufacturing.